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ABSTRACT
Objective To examine whether excluding patients from
the analysis of randomised trials are associated with
biased estimates of treatment effects and higher
heterogeneity between trials.
DesignMeta-epidemiological study based on a collection
of meta-analyses of randomised trials.
Data sources 14 meta-analyses including 167 trials that
compared therapeutic interventions with placebo or non-
intervention control in patients with osteoarthritis of the
hip or knee and used patient reported pain as an
outcome.
Methods Effect sizes were calculated from differences in
means of pain intensity between groups at the end of
follow-up, divided by the pooled standard deviation.
Trials were combined by using random effects meta-
analysis. Estimates of treatment effects were compared
between trials with and trials without exclusions from the
analysis, and the impact of restricting meta-analyses to
trials without exclusions was assessed.
Results 39 trials (23%) had included all patients in the
analysis. In 128 trials (77%) some patientswere excluded
from the analysis. Effect sizes from trials with exclusions
tended to be more beneficial than those from trials
without exclusions (difference −0.13, 95% confidence
interval −0.29 to 0.04). However, estimates of bias
between individual meta-analyses varied considerably
(τ2=0.07). Tests of interaction between exclusions from
the analysis and estimates of treatment effects were
positive in five meta-analyses. Stratified analyses
indicated that differences in effect sizes between trials
with and trials without exclusions were more pronounced
inmeta-analyseswith high between trial heterogeneity, in
meta-analyses with large estimated treatment benefits,
and in meta-analyses of complementary medicine.
Restriction of meta-analyses to trials without exclusions
resulted in smaller estimated treatment benefits, larger P
values, and considerable decreases in between trial
heterogeneity.
Conclusion Excluding patients from the analysis in
randomised trials often results in biased estimates of
treatment effects, but the extent and direction of bias is
unpredictable. Results from intention to treat analyses
should always be described in reports of randomised
trials. In systematic reviews, the influence of exclusions
from the analysis on estimated treatment effects should
routinely be assessed.
INTRODUCTION
In clinical trials, deviations from protocol and losses to
follow-up often lead to the exclusion of some rando-
mised patients from the analysis.1 2 Patients excluded
after randomisation are unlikely to be representative
of patients remaining in the trial. For example, patients
may not be available for follow-up because they have
an acute exacerbation of their condition or severe side
effects,3 and patients with protocol deviations may
have a worse prognosis than those adhering to the
protocol.4 The selective occurrence and biased hand-
ling of protocol deviations and losses to follow-upmay
lead to results that differ systematically from the true
values. This is generally referred to as attrition bias.2
To ensure that intervention and control groups are
comparable and to prevent attrition bias, all rando-
mised patients should be included in the analysis and
kept in their original groups, regardless of their adher-
ence to the study protocol. In other words, the analysis
should be done according to the intention to treat prin-
ciple, avoiding any selective exclusion of patients after
randomisation.2 5
Meta-epidemiological studies examine the associa-
tion of specific characteristics of a trial, such as conceal-
ment of allocation or blinding of patients, with
estimated treatment effects in a collection of meta-ana-
lyses and their component trials.6 7 The association of
withdrawals, dropouts, and exclusions after randomi-
sation with estimated treatment effects has been
explored in four meta-epidemiological studies of bin-
ary outcomes.1 68-10 The direction and magnitude of
attrition bias varied between different studies accord-
ing to different methods and definitions used and dif-
ferent clinical areas addressed: attrition biasmay result
in both overestimation and underestimation of treat-
ment effects, and its magnitude is difficult to
predict.1 9 11 12 In general, randomised controlled trials
using subjective outcomes are more susceptible to bias
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than trials using objective outcomes such as overall
mortality. A recent study found that bias associated
with the lack of allocation concealment and lack of
blinding was restricted to trials using subjectively
assessed outcomes.12 In trials of osteoarthritis, treat-
ment effects are often evaluated using subjective out-
comes, such as intensity of pain or disability measured
on visual analogue, numerical rating, or Likert scales,
whereas objective binary outcomes, such as mortality,
are addressed rarely. Meta-analyses of osteoarthritis
trials may therefore be particularly prone to attrition
bias associated with exclusions of patients from the
analysis.2
We carried out a meta-epidemiological study to
assess the impact of attrition bias in meta-analyses of
non-binary patient reported outcomes, such as pain
intensity. We examined whether excluding patients
from the analysis were associatedwith biased estimates
of treatment effects and with increased heterogeneity
between trials in meta-analyses of interventions used
for the treatment of pain in osteoarthritis.
METHODS
Search and selection of meta-analyses and component
trials
We searched theCochrane Library,Medline, Embase,
and CINAHL using a combination of keywords and
text words related to osteoarthritis. These were com-
bined with validated filters for systematic reviews and
meta-analyses.13 The last update was carried out on 20
November 2007 (see web extra appendix table 1 for
details of search strategy).
We included meta-analyses of randomised or quasi-
randomised trials in patients with osteoarthritis of the
knee or hip. Trials using an unpredictable allocation
sequence were considered as randomised, trials using
potentially predictable allocationmechanisms, such as
alternation or the allocation of patients according to
their date of birth, were considered as quasi-rando-
mised. Meta-analyses were eligible if they assessed
patient reported pain comparing any intervention
with placebo, sham, or a non-intervention control.
Two reviewers independently evaluated the reports
for eligibility, and disagreements were resolved by dis-
cussion. If necessary a third reviewer was consulted to
reach consensus. Reports of all component trials were
obtained, and no language restrictions were applied.
Data collection and quality assessment
Two reviewers used a standardised form to indepen-
dently extract data from the original reports of indivi-
dual trials on interventions, funding, year of
publication, publication language, design, study size,
blinding of patients, losses to follow-up, exclusions,
handling of missing data, and results. When necessary
we approximated means and measures of dispersion
from figures. For crossover trials we extracted data
from the first period only.14 Disagreements were
resolved by discussion with a third reviewer and sub-
sequent consensus.
Trials were classified to have had no exclusions of
patients from the analysis if there was an explicit state-
ment that all randomised patients were included in the
analysis of the outcome we extracted or if the reported
numbers of patients randomised and analysed on this
outcomewere identical.We classified trials to havehad
exclusions if they explicitly reported exclusions from
the analysis, if the number of patients analysed was
lower than the number of patients randomised, or if it
was unclear whether exclusions from the analysis had
occurred. Concealment of treatment allocation was
considered adequate if the investigators responsible
for patient inclusionwere unable to suspect before allo-
cation which treatment was next—central randomisa-
tion or the use of sequentially numbered, sealed, and
opaque randomisation envelopes was deemed ade-
quate, for example. Blinding of patients was consid-
ered adequate if experimental and control
interventions were described as indistinguishable or if
a double dummy technique was used.2
Outcome measures
The primary outcomewas patient reported pain. If dif-
ferent pain outcomes were reported we extracted one
outcome per study according to a hierarchy described
previously.15 16 If more then one time point was
reported we extracted the latest time point up to three
months after the end of treatment for potentially struc-
ture modifying agents and up to 12 months after the
endof treatment for behaviour changing interventions.
For all other interventions we extracted the outcome at
the end of treatment.
Statistical analysis
We expressed treatment effects as effect sizes by divid-
ing the difference in mean values at the end of follow-
up by the pooled standard deviation. Negative effect
sizes indicate a beneficial effect of the experimental
intervention. If some required data were unavailable
we used approximations as previously described.16 If
a trial was included in more than onemeta-analysis we
inflated standard errors to avoid double counting of
patients—for example, if the control group of a trial
with three arms was included in two different meta-
analyses, we inflated the standard error of the estimate
for the control group by √2. We used standard inverse
variance random effects meta-analyses to combine
effect sizes across trials and calculated the variance esti-
mate τ2 as a measure of heterogeneity.17
Within each meta-analysis we used random effects
meta-analysis to estimate effect sizes separately for
trials with and trials without exclusions of patients
from the analysis. Then we derived differences
between estimates from trials with exclusions and trials
without exclusions for each meta-analysis and com-
bined these differences using randomeffectsmeta-ana-
lysis, which fully accounted for the variability in bias
betweenmeta-analyses.7A negative difference in effect
sizes indicates that trials with exclusions show a more
beneficial treatment effect. Meta-analyses including
only trials with exclusions or only trials without
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exclusions did not contribute to the analysis. Formal
tests of interaction between exclusions from the analy-
sis and estimated treatment benefits were done sepa-
rately for each meta-analysis based on z scores for
estimated differences in effect sizes between trials
with and trials without exclusions and the correspond-
ing standard errors. We carried out stratified analyses
accompanied by interaction tests according to the fol-
lowing characteristics: between trial heterogeneity in
the overall meta-analysis (low, τ2<0.06, v high,
τ2≥0.06), treatment benefit in the overall meta-analysis
(small, effect sizes >−0.5, v large, effect sizes ≤−0.5),15 18
and type of intervention assessed in the meta-analysis
(drug v other interventions, conventional v comple-
mentary medicine). A τ2 of 0.06 corresponds to a dif-
ference between smallest and largest effect sizes of
about 1 standard deviation unit.19 To control con-
founding by concealment of allocation and by patient
blinding, we used stratification by these factors to
derivedifferencesbetween trialswith and trialswithout
exclusions adjusted for concealment of allocation and
adjusted for patient blinding.
Finally, we compared pooled effect sizes, between
trial heterogeneity, precision defined as the inverse of
the standard error, and P values for pooled effect sizes
between overall random effects meta-analyses includ-
ing all trials and restricted meta-analyses including
trials without exclusions only. Measures were com-
pared using scatter plots and Wilcoxon rank tests for
paired observations. P values were two sided. All ana-
lyses were done in STATA version 10.
RESULTS
Characteristics of included meta-analyses
Overall, 354 reports of reviews of interventions in
osteoarthritis were identified (fig 1). Seventeen reports
including 21 meta-analyses were eligible. Of these, 14
meta-analyses included at least one trial with and one
without exclusion of patients from the analysis and
contributed to the study.16 20-30 Table 1 shows the char-
acteristics of the included meta-analyses. The meta-
analyses included 167 trials in 41 170 patients. Eight
meta-analyses assessed the efficacy of drug inter-
ventions and five assessed interventions in comple-
mentary medicine. The number of trials per meta-
analysis ranged from three to 24 (median 11) and the
number of patients contributing to the meta-analysis
from 278 to 13 659 (median 1731). The pooled effect
sizes derived from random effects meta-analyses
Reports of reviews of interventions for osteoarthritis (n=354)
Reports of meta-analyses in osteoarthritis (n=151)
Eligible reports of meta-analyses (n=17)
Trials without exclusions of
patients from analysis (n=39)
Trials with exclusions of
patients from analysis (n=128)
Eligible meta-analyses (n=21, including 190 trials)
Reports excluded (n=203): 
  No systematic reviews (n=23)
  No meta-analyses (n=180)
Meta-analyses included in study (n=14, including 167 trials)
Meta-analyses excluded (n=7): 
  No trials with exclusions (n=1)
  No trials without exclusions (n=6)
Reports excluded (n=134): 
  No continuous pain outcomes (n=43)
  Duplicate topics (n=83) 
  Active control interventions (n=8)
Fig 1 | Identification of meta-analyses in osteoarthritis
Table 1 | Characteristics of included meta-analyses
Interventions
Drug
intervention
Complementary
medicine No of trials* No of patients Effect size (95% CI)
Heterogeneity τ2
(P value)
Exercise v control20 No No 16 2700 −0.29 (−0.38 to −0.21) 0.00 (0.41)
Viscosupplementation v placebo21 Yes No 22 3046 −0.33 (−0.50 to −0.17) 0.11 (<0.001)†
Self management v control22 No No 12 5812 −0.07 (−0.15 to 0.02) 0.01 (0.15)
Glucosamine v placebo23 Yes Yes 15 1518 −0.61 (−0.94 to −0.28)‡ 0.35 (<0.001)†
Diacerein v placebo25 Yes No 6 1613 −0.24 (−0.35 to −0.13) 0.00 (0.33)
Acetaminophen (paracetamol) v placebo24 Yes No 5 1849 −0.23 (−0.37 to −0.10) 0.01 (0.13)
Opioids v placebo26 Yes No 13 3713 −0.39 (−0.47 to −0.31) 0.00 (0.26)
Oral NSAIDs v placebo29 Yes No 24 13659 −0.40 (−0.49 to −0.31) 0.04 (<0.001)
Topical NSAIDs v placebo29 Yes No 9 1302 −0.47 (−0.65 to −0.29) 0.04 (0.018)
Low-level laser therapy v placebo28 No Yes 8 347 −0.47 (−0.98 to 0.04) 0.42 (<0.001)†
TENS v sham28 No Yes 10 358 −0.88 (−1.36 to −0.39)‡ 0.52 (<0.001)†
Weight reduction v control27 No No 3 278 −0.12 (−0.33 to 0.09) 0.01 (0.34)
Acupuncture v control30 No Yes 6 1540 −0.49 (−0.78 to −0.19) 0.12 (<0.001)†
Chondroitin v placebo16 Yes Yes 20 3833 −0.72 (−0.95 to −0.49)‡ 0.23 (<0.001)†
NSAIDs=non-steroidal anti-inflammatory drugs; TENS=transcutaneous electrical nerve stimulation. Effect sizes and corresponding 95% confidence intervals were derived from random effects
meta-analyses of all trials. Negative effect sizes indicate a beneficial effect of experimental intervention. Meta-analyses are ordered according to year of publication.
*Number of trials totals 169 as two trials were included each in two different meta-analyses.
†Meta-analyses considered to have high heterogeneity between trials (τ2≥0.06).
‡Meta-analyses considered to have large estimated treatment benefit according to overall meta-analysis including all trials (pooled effect size ≤−0.50).
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including all trials ranged from−0.07, indicating essen-
tially no benefit, to −0.88, representing a large benefit
(median−0.40).Allmeta-analyses favoured the experi-
mental intervention and 11 of 14 showed statistically
significant differences between experimental and
control intervention at the conventional level of
P=0.05. The variance τ2 as a measure of between trial
heterogeneity varied between 0.00 and 0.52 (median
0.04, table 1).
Characteristics of component trials
Table 2 shows the characteristics of included trials. In
total, 39 of the 167 trials (23%) included all randomised
patients in the analysis. In 114 trials (69%) there were
exclusions, and in 14 trials (8%) it was unclear whether
exclusions hadoccurred.Exclusions ranged from0.1%
to 40% (median 7.2%). Trials with exclusions were less
likely to provide information on losses to follow-up
(P=0.002). Data imputations using the last observation
carried forwardmethodwere reported by 27% of trials
with exclusions and 49% of trials without exclusions,
multiple imputation by 4% and 15%, and for 68% and
15% it was unclear how the trialists dealt with missing
data in the analysis. Trials with exclusions were pub-
lished earlier (mean 1998, SD 6) than trials without
exclusions (2001, SD 4; P=0.002) and tended to report
adequate concealment of allocation and sample size
calculations less often. No clear differences were
observed for blinding, reporting of primary outcome,
type of intervention, source of funding, and language
of publication.
Effect of exclusions on estimates of treatment effects
Figure 2 shows the forest plot of differences in effect
sizes between trials with and trials without exclusions
across the 14 meta-analyses. On average, treatment
effects were more beneficial in trials with exclusions
than in trials without exclusions (difference in effect
sizes −0.13, 95% confidence interval −0.29 to 0.04,
P=0.13), but the variability in bias between meta-ana-
lyses was considerable (τ2=0.07, P<0.001). Differences
in effect sizes ranged from −0.82 to 0.35. Tests of inter-
action between exclusions from the analysis and esti-
mates of treatment effects were positive at the
conventional level of P=0.05 in five meta-analyses: in
four meta-analyses estimated effects were more bene-
ficial in trials with exclusions from the analysis and in
one meta-analysis estimated effects were more benefi-
cial in trials without exclusions (fig 2).
Figure 3 presents results of stratified analyses. Differ-
ences between trials with and trials without exclusions
were evident in meta-analyses with a high degree of
between trial heterogeneity, but not in meta-analyses
with low between trial heterogeneity (P for interaction
<0.001). Similarly, differences weremore pronounced
in meta-analyses with large estimated treatment bene-
fits in the overall meta-analysis compared with meta-
analyses with small estimated benefits (P for inter-
action<0.001) and inmeta-analyses of complementary
interventions compared with conventional medicine
(P for interaction <0.001). When stratifying for these
characteristics, the variability in bias decreased consid-
erably. For example, τ2 was 0.03 in meta-analyses of
complementary medicine and 0.02 in meta-analyses
of conventionalmedicine.When adjusting for conceal-
ment of allocation (−0.11, 95% confidence interval
Table 2 | Characteristics of component trials
Characteristics
No (%) of trials with
exclusions (n=128)
No (%) of trials
without exclusions
(n=39) P value
Losses to follow-up:
None* 1 (1) 9 (23)
0.002
<10% 32 (26) 6 (15)
10-20% 26 (20) 6 (15)
>20% 26 (20) 17 (44)
Information unavailable 43 (33) 1 (3)
Imputation of missing data:
Last observation carried forward 35 (27) 19 (49)
<0.001
Multiple imputation 5 (4) 6 (15)
Explicitly no losses to follow-up* 1 (1) 8 (21)
Information unavailable 87 (68) 6 (15)
Adequate concealment of allocation:
Yes 24 (19) 15 (38)
0.07
No or unclear 104 (81) 24 (62)
Described as double blind:
Yes 88 (69) 28 (72)
0.74
No 40 (31) 11 (28)
Adequate blinding of patients:
Yes 60 (46) 21 (54)
0.43
No or unclear 68 (54) 18 (46)
Primary outcome:
Reported 70 (55) 27 (69)
0.27
Not reported 58 (45) 12 (31)
Sample size calculation:
Reported 50 (39) 23 (59)
0.12
Not reported 78 (61) 16 (41)
No of patients randomly assigned:
>200 48 (38) 21 (54)
0.20
≤200 80 (62) 18 (46)
Drug intervention:
Yes 85 (66) 28 (72)
0.53
No 43 (34) 11 (28)
Complementary medicine:
Yes 44 (34) 15 (38)
0.62
No 84 (66) 24 (62)
Funding by non-profit organisation:
Yes 30 (24) 9 (23)
0.96
No or unclear 98 (76) 30 (77)
Language of primary report:
English 120 (94) 38 (97)
0.49
Non-English 8 (6) 1 (3)
Year of publication:
1980-9 17 (13) 0 (0)
0.0031990-9 49 (38) 10 (26)
2000-7 62 (49) 29 (74)
P values are derived from logistic regression models adjusted for clustering of trials within meta-analyses.
Comparisons of frequency of concealment of allocation, description of double blinding, adequate blinding of
patients, trial size, type of intervention, funding, language of publication, and publication year were preplanned.
*One trial reporting that no patient was lost to follow-up used the last observation carried forward approach to
impute some missing outcome data.
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−0.28 to 0.05, P=0.18) or patient blinding (−0.15, −0.30
to 0.00, P=0.047), average differences between trials
with and trials without exclusions of patients were
robust. In both adjusted analyses the variability in
bias between meta-analyses was much the same as in
the primary analysis, with variance estimates τ2 of 0.08
(P<0.001) and 0.06 (P<0.001), respectively.
Impact of restricting meta-analyses to trials without
exclusions
Figure 4 presents comparisons of overall meta-ana-
lyses including all trials with restricted meta-analyses
including trials without exclusions only. After the
restriction the number of trials included in a single
meta-analysis decreased from amedian of 11 to amed-
ian of 2 and the number of patients from a median of
1731 to a median of 401. Estimates of treatment bene-
fits decreased in 10meta-analyses and increased in four
(P=0.10). Between trial heterogeneity decreased in 12
meta-analyses and increased in one (P=0.006). For one
meta-analysis only one trial hadno exclusions from the
analysis, and no between trial heterogeneity could be
estimated after the restriction. 30 Precisions of pooled
effect size estimates decreased in nine meta-analyses
and increased in five (P=0.25). P values became larger
in 10 meta-analyses and smaller in four (P=0.016).
After the restriction to trials without exclusions only,
six meta-analyses lost statistical significance at the con-
ventional level of P=0.05.
DISCUSSION
In thismeta-epidemiological study of 14meta-analyses
and 167 trials we found that excluding randomised
patients from the analysis often resulted in biased esti-
mates of treatment effects. The average estimate of bias
of a difference in effect size of −0.13 may seem small
(fig 2), however it corresponds to one quarter to one
half of a typical treatment effect found for interventions
in osteoarthritis.15 The impact of exclusions on esti-
mates of treatment effects seemed most pronounced
in meta-analyses with large treatment benefits, meta-
analyses on complementary interventions, and meta-
analyses with a high degree of heterogeneity between
trials, but the extent and direction of bias may be
unpredictable in a specific situation. Tests of inter-
action between exclusions from the analysis and esti-
mates of treatment effects were statistically significant
in five meta-analyses; in four of these meta-analyses,
estimated treatment effects were less beneficial in trials
without exclusions.
When restricting meta-analyses to trials without
exclusions, P values increased in most cases and six
meta-analyses lost statistical significance at P=0.05
(fig 4). This increase in P values was not only due to a
loss of statistical power.31 As a result of the restriction
the between trial heterogeneity τ2 decreased consider-
ably. Therefore the average loss of statistical precision
of random effects meta-analyses was smaller than what
could be expected after the exclusion of over half the
trials. Only in five meta-analyses was there a relevant
loss of precision after the restriction, in six meta-ana-
lyses the statistical precision remainedmuch the same,
and in three meta-analyses the precision increased.
Strengths and limitations of the study
In practice, various definitions of the intention to treat
principle are used.5 32 In our study we did not rely on
statements in the trial reports on whether an intention
to treat analysis was done or not. Rather we required
explicit information about the flow of patients through
the study3334 or clear statements that all randomised
patients were included in the analysis. Some might
argue that our distinction between trials with and trials
without exclusions from the analysis was overly strin-
gent. The exclusion of only a small proportion of
patients from the analysis, for example,may be consid-
ered unlikely to have any impact on estimated treat-
ment benefits. We would expect that any bias
associated with exclusions from the analysis will
increase with the number of exclusions. Therefore
the overall estimate of bias might increase with the
selection of a less rigorous cut off. Others may argue
that our classification was not stringent enough and
that we should have required an affirmative statement
that no crossovers had occurred and that all rando-
mised patients were included in the analysis in the
group to which they were originally allocated. Only
seven of the 167 included trials (4%) explicitly pro-
vided this information, so we were unable to examine
this issue.
As with other meta-epidemiological studies,6 9 our
study is based on published information and depends
on the quality of the trial reports. Even though the qual-
ity of reporting is generally low,35 36 we were able to
  Exercise20
  Viscosupplementation21
  Self management22
  Glucosamine23
  Diacerein25
  Acetaminophen (paracetamol)24
  Opioids26
  Oral NSAIDs29
  Topical NSAIDs29
  Low level laser therapy28
  TENS28
  Weight reduction27
  Acupuncture30
  Chondroitin16
Overall: τ2=0.07, P<0.001
-0.11 (-0.40 to  0.18)
-0.37 (-0.62 to -0.12)
-0.03 (-0.62 to  0.11)
-0.72 (-1.38 to -0.05) 
 0.16 (-0.07 to  0.39)
-0.22 (-0.41 to -0.04)
 0.11 (-0.11 to  0.34)
-0.03 (-0.22 to  0.17)
 0.35 (0.03  to  0.68) 
-0.15 (-1.26 to  0.96) 
-0.15 (-1.00 to  0.70)
 0.28 (-0.19 to  0.75)
-0.36 (-0.80 to  0.08) 
-0.82 (-1.08 to -0.57)
 -0.13 (-0.29 to 0.04)
0.46
0.003
0.68
0.034
0.18
0.018
0.32
0.79
0.034
0.79
0.73
0.25
0.11
<0.001
-1.5 -1.0 -0.5 0 0.5 1.0 1.5
Intervention
Trials with
exclusions
more beneficial
Trials without
exclusions
more beneficial
Difference in
effect sizes
(95% CI)
Difference in
effect sizes
(95% CI)
P for
interaction
Fig 2 | Difference in effect sizes between 128 trials with and 39 trials without exclusions of
patients from analysis. A negative difference in effect sizes indicates that trials with exclusions
of patients from analysis show more beneficial treatment effects. P values are for interaction
between exclusions from analysis and effect sizes. NSAIDs=non-steroidal anti-inflammatory
drugs; TENS=transcutaneous electrical nerve stimulation
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determine in all but 14 trials whether exclusions from
the analysis had occurred. Compared with previous
meta-epidemiological studies,1 6 8-10 misclassification
of trials due to inadequate reporting11 is therefore less
likely to have introduced bias in our study. At least two
thirds of the trials included in our studyhad incomplete
outcome data. Two approaches towards imputation of
missing data are generally used to replacemissing data
and allow an intention to treat analysis: the last obser-
vation carried forward method and multiple imputa-
tion. We were unable to examine whether the
approachused for data imputation influences estimates
of treatment effects because of the strikingly low qual-
ity of reporting.32 34 35 Other types of bias that may
affect the results of randomised trials include selection
bias due to inadequate concealment of allocation, and
performance and assessor bias due to a lack of blinding
of patients and therapists.2 12 In our study, the observed
association between exclusions of patients from the
analysis and estimates of treatment effects could be
confounded by concealment of allocation: trials with
exclusions tended to report adequate concealment of
allocation less often than trials without exclusions. This
correlationmay have resulted in spurious associations.
When accounting for concealment of allocation in a
sensitivity analysis, however, we found our results to
be robust. Finally, characteristics of meta-analyses
were also correlated. For example, meta-analyses in
complementary medicine were likely to show large
treatment benefits and a high degree of heterogeneity
between trials. Our understanding of the interplay of
these characteristics is incomplete. Therefore the
results of our stratified analyses (fig 3) should to be
interpreted with caution. A detailed examination of
that problem would require a much larger set of
meta-analyses.
Context
As is the case for other types of bias,12 the extent of
attrition bias might depend on the type of outcome.
Ours is the first meta-epidemiological study to investi-
gate pain as a patient reported outcome, a measure
extensively used in research on osteoarthritis.15 This
outcome is more prone to bias than objective binary
outcomes such as mortality.12 Four studies have exam-
ined the impact of attrition bias on estimates of treat-
ment benefits in randomised controlled trials and
meta-analyses on an odds ratio scale.1 6 8-10 The direc-
tion and magnitude of attrition bias varied between
different studies according to different methods and
definitions used, different clinical areas addressed,
and the potential for misclassification of trials because
of inadequate reporting.6 8-10 A recent study used indi-
vidual patient data and found that analyses with
patients excluded showed more beneficial effects of
the experimental treatment than analyses according
to the intention to treat principle.1 Another study of
placebo controlled trials of serotonin reuptake inhibi-
tors sponsored by the pharmaceutical industry found
that the experimental interventionwas favoured less in
intention to treat analyses than in per protocol ana-
lyses. Many published reports of these trials ignored
the results of intention to treat analyses and reported
only the more favourable per protocol analyses.37
Overall
Heterogeneity between trials in overall meta-analysis
  Low
  High
Treatment benefit in overall meta-analysis
  Small
  Large
Drug intervention
  Yes
  No
Complementary medicine
  Yes
  No
-0.13 (-0.29 to 0.04)
0.03 (-0.09 to 0.15)
-0.52 (-0.76 to -0.27)
-0.03 (-0.16 to 0.09)
-0.74 (-1.02 to -0.46)
-0.16 (-0.41 to 0.09)
-0.05 (-0.17 to 0.07)
-0.59 (-0.87 to -0.31)
-0.01 (-0.14 to 0.12)
14
8
6
11
3
8
6
5
9
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Fig 3 | Differences in effect sizes between 128 trials with and 39 trials without exclusions of patients from analysis stratified
according to four characteristics of meta-analyses. See table 1 for a description of meta-analyses according to these
characteristics. A τ2 <0.06 indicates low between trial heterogeneity and a τ2 ≥0.06 high between trial heterogeneity. An effect
size >−0.5 indicates a small benefit of the experimental intervention and an effect size ≤−0.5 a large benefit. Meta-analyses are
ordered according to year of publication. A negative difference in effect sizes indicates that trials with exclusions of patients
from analysis show a more beneficial treatment effect. Variability in bias between-meta-analyses is expressed as
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Several authors pointed out that attrition bias can go in
either direction and is difficult to predict for a specific
situation,1 2 which is in accordance with our findings of
highly variable effects between meta-analyses. Pre-
vious meta-epidemiological studies, which examined
the effect of exclusions from the analysis,1 6 8-10 might
be reanalysed in the light of our results to examine
the variability in bias associated with exclusions.
Implications
The intention to treat principle aims to compare
patients in the groups to which they were originally
allocated. The most stringent interpretation of inten-
tion to treat includes the analysis of all patients, regard-
less of whether they were eligible, received treatment,
and adhered to the protocol.5 In practice, various inter-
pretations are used, some of which allow for exclusions
after randomisation. Many trialists exclude rando-
mised patients who did not receive at least one dose
of the allocated intervention, whereas others exclude
patients found retrospectively to be ineligible.5 38 Both
approaches to excluding patients from the analysis
may produce unbiased estimates if patients and treat-
ing doctors are unaware of the allocated intervention
and if the decision to exclude patients is based solely on
information collected before randomisation and unre-
lated to group assignment and clinical outcome.38 In
addition, exclusions from the analysis owing to ran-
domly missing outcome data may be less problematic
than the selective exclusion of patients owing to proto-
col violations. These assumptions are hardly ever ver-
ifiable: details on the flow of participants through the
various stages of a trial and descriptions of procedures
used to determinewhether patients shouldbe excluded
from the analysis are often omitted from published
reports of randomised trials.5 34 Therefore it is difficult
to determine from published information whether
reported exclusions from the analyses resulted in
bias,2 and strict adherence to the intention to treat prin-
ciple should be advocated.33 39
The purpose of an intention to treat analysis is to
preserve an unbiased treatment allocation and the
prognostic balance between treatment groups. In con-
trast, per protocol analyses include only those patients
who received treatment as defined in the study proto-
col and provided outcome data. Patients excluded
from per protocol analyses are likely to be different
from those analysed: they may have had an acute
exacerbation of the studied condition or experienced
side effects of the evaluated intervention.3 Trials with-
out exclusions more often reported imputations of
missing data than thosewith exclusions. The last obser-
vation carried forward approach was used most often:
missing values were replaced by the last value
observed. This method is popular for imputation of
missing data in musculoskeletal research4041 but leads
to overly precise estimates and potential bias.42 43 Mul-
tiple imputation ismore difficult to carry out but avoids
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those problems44: each missing value is replaced by
multiple simulated values, and the analysis of the
resulting multiple versions of the complete dataset
can account for the uncertainty about missing data.
The CONSORT statement urges transparent report-
ing of the flow of participants through the various
stages of a trial, including a description of withdrawals
and losses to follow-up and the reasons for exclusions
from the analysis.33 39 In our view a detailed description
of strategies used to handle missing outcome data is
also essential.
Conclusions
The box summarises our recommendations for prac-
tice. Excluding patients from the analysis often results
in biased estimates of treatment effects in randomised
trials. To avoid potential attrition bias, trialists should
ensure low dropout rates and high compliance rates
and minimise missing outcome data. Results of inten-
tion to treat analyses, which are based on the inclusion
of all patients in the analysis in the group to which they
were originally allocated, should always be reported.
Sensitivity analyses, which are restricted to patients
adhering to the protocol,may be described in addition.
In systematic reviews and meta-analyses, data
extraction should be based on results from analyses
of all randomised patients, whenever possible. The
influence of exclusions from analysis on estimated
treatment benefits should be routinely assessed in stra-
tified analyses. This may be particularly important in
complementary medicine, in the presence of high het-
erogeneity between trials, andwhen pooled effect sizes
indicate a large benefit of evaluated interventions.
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